Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study
机构：[1]Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA;[2]Shenzhen Genoimmune Med Inst GIMI, Shenzhen, Peoples R China;[3]Fu Dan Univ, BMT Ctr, Shanghai Dao Pei Hosp, Shanghai, Peoples R China;[4]Arizona State Univ, Biodesign Inst, Dept Biomed Informat, Tempe, AZ USA;[5]Hebei Yanda Lu Daopei Hosp, Beijing, Peoples R China;[6]Beijing Aerosp Gen Hosp, Dept Hematol, Beijing, Peoples R China;[7]Peking Univ, Peoples Hosp, Dept Pediat Hematol, Beijing, Peoples R China;[8]Beijing Childrens Hosp, Capital Med Univ, Dept Pediat Hematol, Beijing, Peoples R China;临床科室医技科室新生儿中心血液中心首都医科大学附属北京儿童医院[9]Air Force Gen Hosp, Dept Hematol, PLA, Beijing, Peoples R China;[10]First Peoples Hosp Yunnan Prov, Dept Hematol, Kunming, Yunnan, Peoples R China;[11]Ming Ji Hosp, Dept Hematol, Nanjing, Peoples R China
第一作者机构：[1]Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA;[2]Shenzhen Genoimmune Med Inst GIMI, Shenzhen, Peoples R China;
推荐引用方式(GB/T 7714)：
Chang Lung-Ji,Dong Lujia,Liu Yu-Chen,et al.Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study[J].BLOOD.2016,128(22):-.
APA：
Chang, Lung-Ji,Dong, Lujia,Liu, Yu-Chen,Tsao, Shih-Ting,Li, Ya-Chen...&Li, Dong.(2016).Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study.BLOOD,128,(22)
MLA：
Chang, Lung-Ji,et al."Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study".BLOOD 128..22(2016):-
医学